ClinicalTrials.gg
RecruitingNCT07764900Updated Aug 14, 2026

Transjugular and Transfemoral Embolization for Varicocele.

An interventional study of Percutaneous Varicocele Embolization Using N-Butyl Cyanoacrylate (NBCA) in Varicocele, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to male participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2026, registered Aug 2026).
  • Started Apr 2026; still recruiting 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
16 Years to 60 Years
Sex
Male
01

Study summary

This prospective study will evaluate two different approaches for performing embolization to treat varicocele, a condition in which the veins around the testicle become enlarged. Thirty patients with varicocele will undergo embolization using either a transjugular approach, through a vein in the neck, or a transfemoral approach, through a vein in the groin. The choice of approach will depend on the patient's venous anatomy and the feasibility of the procedure. Patients will be followed up at one and three months after the procedure to assess treatment effectiveness, symptom improvement, and any complications.

02

Conditions studied

  • Varicocele

Browse trials for

03

In context

Varicocele

53 studies on the registry are indexed under Varicocele; 15 are open to participants now.

This study's planned enrollment of 30 is below the median of 72 across 36 interventional studies indexed under Varicocele.

Browse Varicocele studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male patients aged 16-60 years. 2. Clinically palpable varicocele (Grade II or III) or subclinical varicocele associated with abnormal semen parameters.

    3. Recurrent varicocele following previous surgical treatment. 4. Presence of scrotal pain, testicular atrophy, or infertility attributed to varicocele.

    5. Willingness to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

- 1. Secondary varicocele due to a retroperitoneal mass or renal vein obstruction.

2. Known allergy to iodinated contrast media. 3. Coagulation disorders or to endovascular procedures.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Percutaneous Varicocele Embolization

    Procedure: Percutaneous Varicocele Embolization Using N-Butyl Cyanoacrylate (NBCA)

Interventions

  • ProcedurePercutaneous Varicocele Embolization Using N-Butyl Cyanoacrylate (NBCA)

    Percutaneous varicocele embolization will be performed under fluoroscopic guidance using a transvenous approach, either transfemoral or transjugular, according to the venous anatomy and operator preference. Selective catheterization of the internal spermatic vein will be performed, followed by embolization using N-butyl cyanoacrylate (NBCA) glue. Technical success will be assessed by completion venography demonstrating occlusion of the targeted varicocele veins and absence of significant residual venous reflux.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Measured by the Visual Analog Scale (VAS).

    Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. A decrease in the VAS score indicates improvement in pain. The change in VAS score from baseline to 1 month after varicocele embolization will be assessed.

    Time frame: 1 month after the procedure

Secondary outcomes

  1. Change in Pain Intensity Measured by the Visual Analog Scale (VAS) at 3 Months.

    Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. A decrease in the VAS score indicates improvement in pain. The change in VAS score from baseline to 3 months after varicocele embolization will be assessed.

    Time frame: 3 months after the procedure

  2. Change in Maximum Diameter of the Pampiniform Plexus Veins on Doppler Ultrasound

    The maximum diameter of the pampiniform plexus veins will be measured using color and spectral Doppler ultrasound before and after varicocele embolization. A decrease in the maximum venous diameter indicates improvement. The change in venous diameter from baseline to 3 months after the procedure will be assessed.

    Time frame: 3 months after the procedure

  3. Resolution of Venous Reflux on Doppler Ultrasound

    Venous reflux will be assessed using color and spectral Doppler ultrasound. Resolution of reflux will be defined as the absence of demonstrable venous reflux after varicocele embolization. The presence or absence of venous reflux will be assessed at 3 months after the procedure.

    Time frame: 3 months after the procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764900
Lead sponsor
Sohag University
Responsible party
Arsanious Maher Adib (Resident of Diagnostic and Interventional Radiology, Sohag University) — Principal investigator
First posted
Aug 14, 2026
Start date
Apr 10, 2026
Primary completion
Mar 10, 2027 (estimated)
Completion
May 10, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

arsanious Maher adib, MBBCh
Contact
arsanuoesmaher@gmail.com
+201287522810

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion